Kaposi's sarcoma secondary prevention: Difference between revisions
Shyam Patel (talk | contribs) No edit summary |
Ahmed Younes (talk | contribs) |
||
| Line 16: | Line 16: | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Revision as of 14:56, 30 May 2019
|
Kaposi's sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Kaposi's sarcoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Kaposi's sarcoma secondary prevention |
|
Risk calculators and risk factors for Kaposi's sarcoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Secondary prevention of Kaposi's sarcoma involves anti-retroviral therapy which can improve the CD4 T cell count.
Secondary Prevention
Secondary prevention of Kaposi's sarcoma involves anti-retroviral therapy which can improve the CD4 T cell count. Lower CD4 T cell counts (below 150 cells per microliter) are associated with worse prognosis and will result in worsening complications. Highly-active anti-retroviral therapy is important for prevention of worsening disease in patients who have Kaposi's sarcoma.[1]
References
- ↑ Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M; et al. (2008). "Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy". Br J Cancer. 99 (5): 800–4. doi:10.1038/sj.bjc.6604520. PMC 2528138. PMID 18665172.